-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Legend Biotech, Lowers Price Target to $48

Benzinga·12/08/2025 15:18:31
Listen to the news
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price target from $54 to $48.